Phaseline

Targets › PDCD1

PDCD1 (Programmed cell death protein 1): drug programs, companies and trials

226 programs from 147 companies in 2804 trials: 1798 Phase 2, 579 Phase 1, 367 Phase 3, 60 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. (UniProt, Q15116)

Open in Phaseline: the race on PDCD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicBCG Solution
Glucagon-like peptide 1 receptor agonist
GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274Phase 4Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss …Nov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Chen XiaopingPD-1 monoclonal antibody
PD-1 checkpoint inhibitor
PDCD1Phase 4HCCDec 2027
Shanghai Pulmonary Hospital, Shanghai, ChinaPD-1/PD-L1 inhibitor
PD-1/PD-L1 pathway inhibitor; anti-PD-1 or anti-PD-L1 monoclonal antibody
PDCD1, CD274Phase 4NSCLC (Non-small Cell Lung Cancer)Oct 2028
GSKDostarlimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; Colonic Neoplasms; Neoplasms, Colon …Nov 2026
AkesoCadonilimab (AK104)
Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor
PDCD1, CTLA4Phase 3Hepatocellular Carcinoma; Cervical Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma; NSCLC (Non-small Cell Lung Cancer) …Nov 2026
Samsung BioepisPembrolizumab (SB27)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Stage IINov 2026
BeiGeneTislelizumab (A317)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Non Small Cell Lung Cancer; Urothelial Carcinoma; Non-small Cell Lung Cancer; MSI-H/dMMR Solid Tumors …Nov 2026
Merck & Co. (MSD)Pembrolizumab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Melanoma; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Head and Neck Neoplasms …Nov 2026
Innovent Biologics (Suzhou)IBI363
Mutated IL-2 cytokine fused to anti-PD-1 antibody; combines IL-2 pathway stimulation with
PDCD1, IL2Phase 3Colorectal Cancer; Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer; Melanoma; Solid Tumors or Lymphoma …Nov 2026
Bristol-Myers SquibbNivolumab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Urothelial Cancer; Melanoma; Renal Cell Carcinoma; Metastatic Colorectal Cancer …Nov 2026
Shanghai Henlius BiotechSerplulimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Extensive Stage Small Cell Lung Cancer; Limited-Stage Small Cell Lung Cancer; Non Small Cell Lung Cancer; Metastatic Colorectal Cancer …Nov 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesVSV injection
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Hepatocellular Carcinoma (HCC); Anal Squamous Cell Carcinoma, Limited-stage; Esophageal Neoplasms; Esophagus Cancer …Dec 2026
PfizerSasanlimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Non-muscle Invasive Bladder Cancer; Urothelial Carcinoma Bladder; Metastatic Renal Cell Carcinoma; Advanced Clear Cell Renal Carcinoma (Ccrcc)Dec 2026
AmgenABP 234
PD-1 inhibitor (pembrolizumab biosimilar)
PDCD1Phase 3Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC); Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerDec 2026
Qilu PharmaceuticalPembrolizumab (QL2107)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3NSCLC; Carcinoma, Non-Small-Cell Lung; Extensive-stage Small Cell Lung Cancer; Advanced Solid TumorDec 2026
Chia Tai Tianqing Pharmaceutical GroupPenpulimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Advanced Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma; Advanced Pancreatic Cancer; Nasopharyngeal Neoplasms …Dec 2026
Sichuan Baili PharmaceuticalTislelizumab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Extensive-stage Small-cell Lung Cancer; Urothelial Carcinoma; Esophageal Squamous Cell CarcinomaDec 2026
RemeGenToripalimab (JS001)
Programmed cell death protein 1 antagonist
PDCD1Phase 3Urothelial Carcinoma; Gastric Cancer; Breast Cancer; Biliary Tract Cancer (BTC) …Dec 2026
Gilead SciencesZimberelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer …Dec 2026
Guangzhou Gloria BiosciencesZimberelimab (GLS-010)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Persistent, Recurrent, or Metastatic Cervical Cancer; Solid TumorDec 2026
AkesoPenpulimab (AK105)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Nasopharyngeal CarcinomaDec 2026
Chinese PLA General HospitalAnti-PD-1 antibody
PD-1 inhibitor
PDCD1Phase 3Ovarian Cancer; Solid Tumor, AdultDec 2026
Johnson & Johnson (Janssen)Cetrelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Urinary Bladder Neoplasms; Bladder Cancer; Prostatic Neoplasms, Castration-Resistant; Neoplasms …Dec 2026
BeOne MedicinesTislelizumab (A317)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3B-cell Malignancies; Metastatic Gastric Adenocarcinoma; Advanced Esophageal Squamous Cell Carcinoma; Advanced Unresectable Gastric Adenocarcinoma …Dec 2026
Mabwell (Shanghai) BioscienceToripalimab (JS001)
Programmed cell death protein 1 antagonist
PDCD1Phase 3Urothelial Carcinoma; Advanced Urothelial CarcinomaDec 2026
BiocadNivolumab (BCD-263)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Advanced MelanomaJan 2027
University Hospital, BordeauxPD-1/PD-L1 ICI + VEGFR-TKI combination
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDR, FLT1, FLT4Phase 3Metastatic Renal Cell CarcinomaJan 2027
AstraZenecaVolrustomig (MEDI5752)
CTLA-4/PD-1 bispecific antibody
CTLA4, PDCD1, TIGITPhase 3Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma …Jan 2027
CelltrionCT-P51
PD-1 inhibitor
PDCD1Phase 3Non Squamous Non Small Cell Lung CancerFeb 2027
Regeneron PharmaceuticalsCemiplimab (REGN2810)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Melanoma; Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma (CSCC); Advanced Non-Small Cell Lung Cancer …Mar 2027
AstraZenecaAZD2936 (rilvegostomig)
Anti-TIGIT/anti-PD-1 bispecific antibody
TIGIT, PDCD1Phase 3Non-small Cell Lung Cancer; Biliary Tract Cancer; Endometrial Cancer; HER2-positive Gastric Cancer …Mar 2027
mAbxience ResearchMB11
PD-1 inhibitor (nivolumab biosimilar)
PDCD1Phase 3Advanced (Unresectable or Metastatic) MelanomaApr 2027
AkesoAK112 (Ivonescimab)
Dual PD-1/TIGIT bispecific antibody
PDCD1, VEGFAPhase 3Pancreatic Cancer; Non-Small Cell Lung Cancer; Platinum-sensitive Ovarian Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC)May 2027
Ono PharmaceuticalNivolumab (ONO-4538)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Gastric Cancer; Pan-tumor; Colorectal Cancer; Rhabdoid Tumor …May 2027
Jiangsu HengRui Medicinecamrelizumab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); Cervical Cancer …May 2027
Chinese PLA General HospitalChidamide
PD-1 checkpoint inhibitor
HDAC, PDCD1Phase 3Newly Diagnosed Acute Myeloid Leukemia (AML); Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma; Acute Monocytic Leukemia; Relapsed/Refractory Acute Myeloid Leukemia …Jun 2027
Tongji HospitalIparomlimab and Tuvonralimab (QL1706)
Bispecific antibody targeting PD-1 and CTLA-4
CTLA4, PDCD1Phase 3Ovarian Clear Cell Carcinoma; Resectable Hepatocellular Carcinoma With High Risk of RecurrenceJun 2027
Sun Yat-sen UniversityPD-1 antibody
Monoclonal antibody targeting PD-1 immune checkpoint
PDCD1Phase 3Hepatocellular Carcinoma; Nasopharyngeal Cancinoma (NPC)Jun 2027
Taiho PharmaceuticalZimberelimab (AB122)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Biliary Tract Cancer; Advanced or Metastatic Solid TumorJun 2027
Fudan UniversityTilelizumab
PD-1 inhibitor
PDCD1Phase 3Gastric CancerJul 2027
Lepu BiopharmaPucotenlimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Recurrent or Metastatic Nasopharyngeal Carcinoma; Head and Neck Squamous Cell Carcinoma; Advanced Solid Tumors; Hepatocellular Carcinoma …Aug 2027
mAbxience ResearchMB12
PD-1 inhibitor
PDCD1Phase 3Non Squamous Non Small Cell Lung CancerSep 2027
BriaCell TherapeuticsRetifanlimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Breast Cancer; Anatomic Stage IV Breast Cancer AJCC v8; Merkel Cell Carcinoma; Recurrent Glioblastoma …Dec 2027
Canadian Cancer Trials GroupPD-1 inhibitor
PD-1 inhibitor
PDCD1Phase 3Unresectable/Metastatic MelanomaDec 2027
Innovent Biologics (Suzhou)Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3MSI-HApr 2028
Chipscreen BiosciencesSintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Colorectal CancerMay 2028
Fudan UniversityCarrelizumab
PD-1 inhibitor
PDCD1Phase 3TNBC - Triple-Negative Breast CancerJul 2028
Sun Yat-sen UniversityPD-1/PD-L1 inhibitors
PD-1 and PD-L1 checkpoint inhibitors
PDCD1, CD274Phase 3Non-small Cell Lung CancerJul 2028
Innovent Biologics (Suzhou)Sindilizumab
PD-1 inhibitor
PDCD1Phase 3Non-Small Cell Lung Cancer; SBRT; Colorectal Cancer Metastatic; Hepatoid Adenocarcinoma of StomachOct 2028
Taizhou Hanzhong biomedicalPucotenlimab (HX008)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Metastatic Colorectal CancerOct 2028
Fudan UniversityPD-1 inhibitors
PD-1 inhibitor
PDCD1Phase 3Esophageal CarcinomaOct 2028
Hutchmedsintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Advanced Endometrial Cancer; Advanced Renal Cell CarcinomaJan 2029
UNICANCERReduced dose intensity of IO
Anti-PD-1, anti-PD-L1, or anti-CTLA-4 checkpoint inhibitor
PDCD1, CD274, CTLA4Phase 3Lung Cancer MetastaticMay 2029
Sun Yat-sen UniversityPD-1/PD-L1 immune checkpoint inhibitor
PD-1/PD-L1 immune checkpoint inhibitor
PDCD1, CD274Phase 3Locally Advanced Non-Small Cell Lung CancerJun 2029
Peking Union Medical College HospitalPD-1 inhibitors
PD-1 pathway inhibitor
PDCD1Phase 3Cervical CancerOct 2029
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAnti-PD-1/PD-L1 Antibody
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 3Esophagus Cancer; Esophageal CancerDec 2030
Ji DongmeiFinotonlimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Squamous Cell Carcinoma of Head and NeckSep 2031
CStone PharmaceuticalsCs-1003 (CS1003)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Hepatocellular Carcinoma–
AbbVieBudigalimab (ABBV-181)
Programmed cell death protein 1 inhibitor
PDCD1Phase 2Hepatocellular Carcinoma; Urothelial Carcinoma; Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Non-Small Cell Lung Cancer …Nov 2026
Sichuan Baili PharmaceuticalSI-B003
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Cervical Cancer …Nov 2026
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2868 injection
Anti-PD-1/TGF-βRII bifunctional fusion protein
PDCD1, TGFBR2Phase 2Pancreatic NeoplasmsNov 2026
Bio-Thera SolutionsBAT1308
anti-PD-1 monoclonal antibody
PDCD1Phase 2Cervical Cancer; Advanced Solid TumorsNov 2026
Beijing Tongren HospitalTislelizumab-jsgr
PD-1 inhibitor
PDCD1Phase 2Head and Neck Squamous Cell CarcinomaNov 2026
Ruijin HospitalPD-1 Inhibitor
Programmed Death-1 (PD-1) inhibitor - intra-arterial administration
PDCD1Phase 2DLBCL; Pancreatic NeoplasmsDec 2026
RenJi HospitalABSK043
PD-1/PD-L1 interaction inhibitor
PDCD1, CD274Phase 2HCC - Hepatocellular CarcinomaDec 2026
CrystalGenomicsCamrelizumab (SHR-1210)
Programmed cell death protein 1 antagonist
PDCD1Phase 2Non Squamous Non Small Cell Lung CancerDec 2026
Sichuan Baili PharmaceuticalPD-1 Monoclonal Antibody
PD-1 inhibitor
PDCD1Phase 2HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma; Triple-negative Breast Cancer; Extensive-stage Small-cell Lung Cancer; Esophageal Cancer …Dec 2026
Navy General Hospital, BeijingPD-1 therapy
PD-1 inhibitor
PDCD1Phase 2Relapsed Classic Hodgkin LymphomaDec 2026
Second Affiliated Hospital, Zhejiang University, School of Medicinecarrizumab
PD-1 inhibitor
PDCD1Phase 2Tumor ImmunityDec 2026
Sir Run Run Shaw HospitalAiparolitoworixureli injection
PD-1/CTLA-4 bispecific monoclonal antibody; dual checkpoint inhibitor blocking PD-1 and CT
PDCD1, CTLA4Phase 2Rectal CancerDec 2026
The Second Affiliated Hospital of Chongqing Medical UniversityAnti-PD-1 antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Chronic Hepatitis bDec 2026
Li ZhangCardenilimab
PD-1 inhibitor
PDCD1Phase 2Esophageal Squamous Cell CarcinomaDec 2026
Ruijin HospitalIparomlimab and Tuvonralimab (QL1706)
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Gastric AdenocarcinomaDec 2026
Sichuan UniversityPD-1 Inhibitor
PD-1 checkpoint inhibitor
PDCD1Phase 2Esophageal Squamous Cell Carcinoma; NSCLCDec 2026
Xinqiao Hospital of ChongqingPD-1 inhibitors
PD-1 checkpoint inhibitor
PDCD1Phase 2NSCLC Stage IV Without EGFR/ALK MutationDec 2026
Jiang FengPD-1 monoclonal antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Head and Neck Squamous CarcinomaDec 2026
First Affiliated Hospital of Zhejiang UniversityPD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection)
PD-1/CTLA-4 dual checkpoint inhibitor antibody
PDCD1, CTLA4Phase 2Bile Duct CarcinomaDec 2026
Shandong Provincial HospitalQL1706 (Iparomlimab and Tuvonralimab)
Combination of PD-1 inhibitor (Iparomlimab) and CTLA-4 inhibitor (Tuvonralimab)
PDCD1, CTLA4Phase 2Locally Advanced Resectable Esophageal Squamous Cell Carcinoma; Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaDec 2026
Shenyang Sunshine PharmaceuticalSSGJ-705
Anti-PD-1 and anti-HER2 bispecific antibody
PDCD1, ERBB2Phase 2Locally Advanced, Recurrent or Metastatic Malignancies; Locally Advanced (Unresectable) or Metastatic Solid TumorsDec 2026
Cancer Institute and Hospital, Chinese Academy of Medical Sciencesanti-PD-1 or PD-L1 antibody
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 2Head and Neck CancerDec 2026
The Second Affiliated Hospital of Chongqing Medical Universityanti-PD-1/anti-PD-L1 antibody
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Chronic Hepatitis BDec 2026
Second Affiliated Hospital, Zhejiang University, School of MedicinePD-1/VEGF dual antibody
PD-1 inhibitor and anti-VEGF antibody
PDCD1, VEGFA, CTLA4Phase 2GlioblastomaJan 2027
Shanghai Chest HospitalPD-1 inhibitor
PD-1 checkpoint inhibitor
PDCD1Phase 2Esophageal Squamous Cell Carcinomas; Esophageal Squamous Cell CarcinomaJan 2027
Tao ZhangPirfenidone
PD-1 monoclonal antibody; immune checkpoint inhibitor
PDCD1Phase 2Colorectal Cancer (CRC)Jan 2027
Peking University Cancer Hospital & InstituteAdebelizumab
PD-1 inhibitor
PDCD1Phase 2SCLC, Extensive StageJan 2027
Sichuan Cancer Hospital and Research InstituteTirelizumab
PD-1 inhibitor
PDCD1Phase 2Esophageal Squamous Cell CarcinomaJan 2027
University Health Network, TorontoOpdualag (BMS-986213)
Anti-LAG3/anti-PD-1 bispecific antibody
LAG3, PDCD1Phase 2Cutaneous MelanomaFeb 2027
Peking University Cancer Hospital & InstituteTirelizumab
PD-1 inhibitor
PDCD1Phase 2Collecting Duct CarcinomaFeb 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPD-1 monoclonal antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Gastric CancerMar 2027
Zhejiang Cancer HospitalPD-1/PD-L1 inhibitors
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Adjuvant RadiotherapyMar 2027
Peking University Cancer Hospital & InstituteQL1706
Anti-PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Esophageal Squamous Cell CarcinomaMar 2027
Sun Yat-sen UniversityTriprolizumab
PD-1 inhibitor
PDCD1Phase 2Adrenocortical CarcinomaMar 2027
baotai LiangTriprilizumab
PD-1 monoclonal antibody
PDCD1Phase 2Prostate CAMar 2027
Zhejiang Cancer HospitalCardunolizumab
PD-1 inhibitor
PDCD1Phase 2Vulvar and Vaginal CancerMar 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPD-1 inhibitors
PD-1/PD-L1 pathway inhibitor
PDCD1Phase 2SCLCMar 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPD-1/PD-L1 inhibitors
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 2Advanced Malignant Solid TumorApr 2027
Sun Yat-sen UniversitySinitilimab
PD-1 monoclonal antibody
PDCD1Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Apr 2027
Peking University Third HospitalCarilizumab
PD-1 inhibitor
PDCD1Phase 2Gastric CancerApr 2027
Sun Yat-sen UniversityIparomlimab and Tuvonralimab (QL1706)
Dual PD-1/CTLA-4 combination antibody
CTLA4, PDCD1Phase 2Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer; Bone and Soft Tissue Tumors; BRAF V600 Colorectal Cancer; Hepatocellular Carcinoma (HCC) …Apr 2027
Tianjin Medical University Cancer Institute and Hospitallparomlimab and Tuvonralimab Injection (QL1706)
Anti-PD-1/CTLA-4 combined antibody
PDCD1, CTLA4Phase 2Endometrial Adenocarcinoma; Metastatic Pancreatic Cancer; HCC; Breast CancerApr 2027
Daihong LiuPD-1 Inhibitor
PD-1 checkpoint inhibitor
PDCD1Phase 2Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)May 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAitua Combination Antibody (QL1706)
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2High-grade Serous Ovarian Cancer (HGSOC)May 2027
The First Affiliated Hospital with Nanjing Medical UniversityTirilizumab
PD-1 inhibitor
PDCD1Phase 2Gastric Cancer, MetastaticMay 2027
Shanghai Zhongshan HospitalPD-1 Monoclonal Antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Intrahepatic Cholangiocarcinoma; Gastric CancerJun 2027
NovartisSpartalizumab (PDR001)
Programmed cell death protein 1 antagonist
PDCD1Phase 2Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Advanced Solid Tumors; Squamous Cell Anal Carcinoma …Jun 2027
Tongji HospitalPD-1 Inhibitor
PD-1 checkpoint inhibitor (specific agent variable per institution: pembrolizumab, sintili
PDCD1Phase 2Solid Tumors; Hepotacellular CarcinomaJun 2027
Dechang DiaoPD-1 Monoclonal Antibody
PD-1 inhibitor
PDCD1Phase 2pMMR/MSS Locally Advanced Rectal Cancer; Short-course Radiotherapy Plus ChemotherapyJul 2027
Xijing HospitalIparomlimab/Tuvonralimab (QL1706)
Bispecific antibody targeting PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Locally Advanced Cervical CancerJul 2027
MacroGenicsLorigerlimab
Bispecific DART protein binding PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Platinum-resistant Ovarian Cancer; Colorectal Cancer; Metastatic Cancer; Pancreatic AdenocarcinomaJul 2027
Mabwell (Shanghai) BiosciencePD-1 inhibitor
PD-1 inhibitor
PDCD1Phase 2Triple-Negative Breast CancerJul 2027
Fudan UniversityPD-L1/PD-1 inhibitor and chemotherapy
PD-L1/PD-1 checkpoint inhibitors combined with chemotherapy
PDCD1, CD274Phase 2NSCLC Stage IVJul 2027
Daihong LiuPD-1Ab21-BCMA CAR-T
BCMA-targeting CAR-T cells secreting PD-1 antibody and interleukin-21 fusion protein
BCMA, PDCD1, IL21Phase 2Multiple MyelomaJul 2027
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAnti-PD-1 inhibitor
PD-1 checkpoint inhibitor
PDCD1Phase 2Liver TransplantationAug 2027
Ruijin HospitalApalulizumab
Dual-function antibody targeting both PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Pancreatic Adenocarcinoma Locally AdvancedAug 2027
Ruijin HospitalDual-Function Antibody PD-1/CTLA-4 (Apalulizumab)
Bispecific antibody targeting PD-1 and CTLA-4 immune checkpoints
PDCD1, CTLA4Phase 2Pancreatic Adenocarcinoma Locally AdvancedAug 2027
Hongmeng YuPD-1 / PD-L1 monoclonal antibody
PD-1 inhibitor
PDCD1Phase 2Nasopharyngeal Carcinoma (NPC)Aug 2027
Fudan UniversityPD-1 antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Esophageal Squamous Cell CarcinomaAug 2027
Jinling Hospital, ChinaPD-1/PD-L1 ICI + VEGFR-TKI
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDRPhase 2Renal Cell Carcinoma (RCC)Aug 2027
Tianjin Medical University Cancer Institute and HospitalIvonescimab (AK112)
PD-1/PD-L2 dual checkpoint inhibitor
PDCD1L2, PDCD1Phase 2ESCCAug 2027
Shenyang Sunshine PharmaceuticalSSGJ-706
PD-1/PD-L1 bispecific antibody
PDCD1, CD274Phase 2First-line Advanced NSCLC PatientsAug 2027
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTirellizumab
PD-1 inhibitor monoclonal antibody
PDCD1Phase 2Oral Cancer; HNSCCAug 2027
The First Affiliated Hospital of Zhengzhou Universitycadonilizumab
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Esophageal Squamous Cell CarcinomaAug 2027
Sixth Affiliated Hospital, Sun Yat-sen UniversityPD-1 monoclonal antibody
PD-1 immune checkpoint inhibitor
PDCD1Phase 2Multiple CancerSep 2027
AgenusBalstilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 2Advanced Melanoma; Metastatic Colorectal Cancer; Advanced Cancer; Gastric Cancer …Sep 2027
Arcus Bioscienceszimberelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 2Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer; Advanced Cancer; Clear Cell Renal Cell CarcinomaSep 2027
Ming-Yuan ChenCarrellimab
PD-1 inhibitor (recombinant monoclonal antibody)
PDCD1Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaSep 2027
Tianjin Medical University Cancer Institute and HospitalIparomlimab
PD-1 and CTLA-4 inhibitor
PDCD1, CTLA4Phase 2Esophageal CancerSep 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyIparomlimab and Tuvonralimab (QL1706)
PD-1 and CTLA-4 dual checkpoint inhibitor
PDCD1, CTLA4Phase 2HCC - Hepatocellular CarcinomaOct 2027
Tianjin Medical University Cancer Institute and HospitalRilapafup α
PD-1 inhibitor
PDCD1Phase 2Biliary Tract Cancer (BTC)Oct 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesIparomlimab/Tuvonralimab
Bifunctional mabpair product of anti-PD-1 and anti-CTLA-4 antibodies
PDCD1, CTLA4Phase 2LOCALLY ADVANCED CERVICAL CANCERSNov 2027
Lei LiuIvonescimab
Bispecific antibody targeting PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Head and Neck Squamous Cell CarcinomaDec 2027
Nanfang Hospital, Southern Medical UniversityIparomlimab and Tuvonralimab Injection (QL1706)
PD-1 and CTLA-4 dual inhibitor
PDCD1, CTLA4Phase 2Hepatecellular CarcinomaDec 2027
Tianjin Medical University Cancer Institute and HospitalTiselizumab
PD-1 inhibitor
PDCD1Phase 2Follicular LymphomaDec 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineIvonescimab (AK112)
Bispecific monoclonal antibody targeting PD-1 and VEGF
PDCD1, VEGFAPhase 2Esophageal Squamous Cell CarcinomaDec 2027
Sixth Affiliated Hospital, Sun Yat-sen UniversityPD-1 inhibitor
PD-1 receptor antagonist
PDCD1Phase 2Rectal Cancer; Neoadjuvant Therapies; Colon Cancer; Immune Checkpoint TherapyDec 2027
Haitao Zhao, MDPD-1 inhibitor
PD-1 inhibitor
PDCD1Phase 2Biliary Tract Cancer (BTC)Dec 2027
Tianjin Medical University Cancer Institute and HospitalPD-1 inhibitors
Programmed death-1 pathway inhibitor
PDCD1Phase 2Intrahepatic Cholangiocarcinoma (Icc)Dec 2027
Innovent Biopharmaceutical Technology (Hangzhou)Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 2Hepatocellular Carcinoma (HCC); Resectable Gastric/Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Squamous Cell Non-small Cell Lung Cancer …Dec 2027
TaiRxSintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 2HCC - Hepatocellular CarcinomaDec 2027
Shandong Provincial HospitalTirelizumab
PD-1 inhibitor
PDCD1Phase 2Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaDec 2027
Bai-Rong XiaTorvolumab
PD-1 inhibitor antibody
PDCD1Phase 2Ovary CancerDec 2027
Chuangzhen ChenPD-1/PD-L1 monoclonal antibodies
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2RadiotherapyJan 2028
CSPC Megalith BiopharmaceuticalEnlonstobart
recombinant human anti-PD-1 monoclonal antibody
PDCD1Phase 2Ovarian Cancer; Head and Neck Squamous Cell CarcinomaApr 2028
Shanghai Zhongshan HospitalIparomlimab and Tuvonralimab (QL1706)
Bifunctional monoclonal antibody composed of PD-1 inhibitor (IgG4) and CTLA-4 inhibitor (I
PDCD1, CTLA4Phase 2Biliary Tract Cancer (BTC)Jun 2028
Shanghai Pulmonary Hospital, Shanghai, ChinaIBI363
PD-1/IL-2α biased agonist
PDCD1, IL2RAPhase 2Unresectable Stage III Non-small Cell Lung CancerJun 2028
Regeneron PharmaceuticalsREGN10597
PD-1-IL2Ra-IL2 immunotherapy
PDCD1, IL2RA, IL2Phase 2Ovarian Cancer; Non Small Cell Lung Cancer; MelanomaJun 2028
Swiss Cancer InstituteIvonescimab
Bispecific PD-1/VEGF antibody
PDCD1, VEGFAPhase 2NSCLCJul 2028
Shandong Cancer Hospital and InstituteIparomlimab/Tuvonralimab
PD-1 inhibitor
PDCD1Phase 2Hepatocellular CarcinomaJul 2028
Changhai HospitalQL1706
Dual PD-1/CTLA-4 antibody
PDCD1, CTLA4Phase 2MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706Aug 2028
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyTirellizumab
PD-1 inhibitor
PDCD1Phase 2Gastric Junction AdenocarcinomaAug 2028
Tianjin Medical University Cancer Institute and HospitalPD-1 antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Locally Advanced Gastric AdenocarcinomaAug 2028
Obstetrics & Gynecology Hospital of Fudan UniversityIvonescimab
TIGIT inhibitor with bispecific antibody targeting TIGIT and PD-1
PDCD1, CTLA4Phase 2Cervical CancersAug 2028
City of Hope Medical CenterAnti-PD1 Monoclonal Antibody
PD-1 inhibitor
PDCD1Phase 2Lung Non-Small Cell CarcinomaOct 2028
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPD-1 inhibitors (extended-dose interval)
PD-1 checkpoint inhibitor
PDCD1Phase 2Triple -Negative Breast CancerDec 2028
The First Affiliated Hospital with Nanjing Medical UniversityPD-1/PD-L1 monoclonal antibody
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 2Primary Central Nervous System Lymphoma (PCNSL)Dec 2028
Kong Fanmingpabolizumab
PD-1 inhibitor
PDCD1Phase 2Non-Small Cell Lung CancerDec 2028
Second Affiliated Hospital of Guangzhou Medical UniversityPD-1/PD-L1/CTLA-4 inhibitors
PD-1, PD-L1, and CTLA-4 checkpoint inhibitors
PDCD1, CD274, CTLA4Phase 2Head/Neck NeoplasmJan 2029
Ruijin HospitalPD-1 antibody
PD-1 pathway inhibition
PDCD1Phase 2Natural Killer/T-cell LymphomaFeb 2029
Nanfang Hospital, Southern Medical UniversityEGFR-TKIs Combined with PD-1 Monoclonal Antibody
EGFR tyrosine kinase inhibitor combined with PD-1 inhibitor
EGFR, PDCD1Phase 2Lung Cancer Non-Small Cell Cancer (NSCLC)Mar 2029
Guangxi Medical UniversityPD-1 inhibitor
PD-1 inhibitor
PDCD1Phase 2Nasopharyngeal CarcinomaMar 2029
Tianjin Medical University Second HospitalPD-1/PD-L1 Inhibitor
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Bladder (Urothelial, Transitional Cell) CancerMar 2029
Sixth Affiliated Hospital, Sun Yat-sen Universitysintlimab
PD-1 monoclonal antibody
PDCD1Phase 2Rectal Squamous Cell CarcinomaJun 2029
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTirelizumab
PD-1 inhibitor
PDCD1Phase 2Head and Neck Squamous Cell CarcinomaFeb 2030
Fudan UniversityAnti-PD1 antibody
PD-1 checkpoint inhibitor
PDCD1Phase 2Locally Recurrent Rectal CancerMar 2030
Virginia Commonwealth UniversityAnti-PD-1 immunotherapy
PD-1 checkpoint inhibitor
PDCD1Phase 2Non-Small Cell Lung CancerJul 2030
Second Affiliated Hospital, Zhejiang University, School of MedicineCarrelizumab
PD-1 inhibitor
PDCD1Phase 2Esophageal Squamous Cell CarcinomaNov 2030
UNC Lineberger Comprehensive Cancer CenterPD-1/PD-L1 inhibitor monotherapy
PD-1 or PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Lung CancerJan 2033
University of California, DavisSystemic (ICI)-based therapy informed by PROphet CB assay and CARG-TT assessment
anti-PD(L)1 immune checkpoint inhibitor(s), with regimen selection guided by proteomic (PR
PDCD1, CD274Phase 2Non-small Cell Lung Cancer Stage IIICMay 2036
Tongji HospitalCardonilizumab
PD-1 inhibitor
PDCD1Phase 2Esophageal Squamous Cell Carcinoma–
Hunan Province Tumor HospitalIBI318
Bispecific anti-PD-1/PD-L1 antibody
PDCD1, CD274Phase 2Non-Small Cell Lung Cancer–
Second Affiliated Hospital, Zhejiang University, School of MedicinePD-1 Antibody
PD-1 inhibitor; checkpoint immunotherapy
PDCD1Phase 2Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer–
AnaptysBioRosnilimab
PD-1 agonist antibody
PDCD1Phase 2Rheumatoid Arthritis; Ulcerative Colitis–
Shanghai Zhongshan Hospitalcardonilizumab
PD-1 and CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 1Biliary Tract CancerDec 2026
AkesoAK129
Bispecific antibody targeting LAG-3 and PD-1
LAG3, PDCD1Phase 1Advanced Malignant Tumors(Stage IA-IB); Non-small Cell Lung Cancer Stage IIIB/IV; Classic Hodgkin LymphomaDec 2026
Rottapharm BiotechBalstilimab (AGEN2034)
Programmed cell death protein 1 antagonist
PDCD1Phase 1Refractory Metastatic Colorectal CancerDec 2026
Ruijin HospitalPD-1 knockout TILs
PD-1 gene knockout in tumor-infiltrating lymphocytes to enhance T cell anti-tumor activity
PDCD1Phase 1Colorectal Cancer (CRC)Dec 2026
Sunshine Guojian Pharmaceutical (Shanghai)SSGJ-705
anti-PD-1 and anti-HER2 bispecific antibody
PDCD1, ERBB2Phase 1Locally Advanced, Recurrent or Metastatic MalignanciesDec 2026
L & L Bio Co., Ltd., Ningbo, ChinaLB1410
anti-PD-1 and anti-TIM-3 bispecific antibody
PDCD1, HAVCR2Phase 1Solid TumorDec 2026
West China HospitalPD-1 mRNA LNP Vaccine (Low Dose, 50 mcg)
mRNA vaccine encoding PD-1, delivered via lipid nanoparticles
PDCD1Phase 1Malignant Tumors; Liver Cancer; Hepatocellular Carcinoma (HCC)Dec 2026
China-Japan Friendship HospitalPD-1/L1 inhibitor
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 1Advanced Solid TumorDec 2026
Sun Yat-sen UniversitySarcVac (Neoantigen vaccine)
PD-1 checkpoint inhibitor
PDCD1Phase 1Soft Tissue Sarcoma (STS)Dec 2026
Peking Union Medical College HospitalCardonilizumab
PD-1 inhibitor monoclonal antibody
PDCD1Phase 1Hepatocellular CarcinomaJan 2027
Inge Marie SvaneTIL therapy with CRISPR PD-1 silencing
CRISPR-Cas9 silencing of PD-1 gene in tumor infiltrating lymphocytes
PDCD1Phase 1Melanoma MetastaticJan 2027
LigaChem BiosciencesAnti-PD-1 monoclonal antibody
PD-1 inhibitor
PDCD1Phase 1Advanced Solid Tumors; Relapsed/Refractory Peripheral T-cell Lymphoma; Renal Cell Carcinoma; Solid Tumors …Jan 2027
Jiangsu Topcel-KH PharmaceuticalAnti-PD1 armored CD19 CAR-T cells
Anti-PD1 armored CD19 CAR-T cell therapy
CD19, PDCD1Phase 1Diffuse Large B Cell LymphomaJan 2027
Bio-Thera SolutionsPembrolizumab (BAT3306)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Carcinoma, Non-Small-Cell LungFeb 2027
Sun Yat-sen UniversityWTX212A
Erythrocyte-αPD-1 antibody conjugates
PDCD1Phase 1Solid Tumor CancerFeb 2027
Johnson & Johnson (Janssen)Cetrelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Carcinoma, Non-small-Cell Lung; NeoplasmsApr 2027
Sichuan Luzhou Buchang BiopharmaceuticalSintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 1Advanced or Metastatic Gastric CancerApr 2027
Shanghai Henlius BiotechPembrolizumab (HLX17)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Non-small Cell Lung CancerApr 2027
Shanghai Juncell TherapeuticsPD-1 antibody
PD-1 inhibitor (low-dose)
PDCD1Phase 1Solid Tumor; Perihilar Cholangiocarcinoma; Esophageal Squamous Cell Carcinoma (ESCC); Lung CancerMay 2027
AstraZenecaAZD7789 (sabestomig)
anti-PD-1 and anti-TIM-3 bispecific antibody
PDCD1, HAVCR2Phase 1Carcinoma, Non-Small-Cell Lung; Advanced or Metastatic NSCLCMay 2027
Beijing Tongren HospitalFinotonlimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 1HNSCCJun 2027
OncoC4AI-081
Bispecific antibody targeting PD-1 and VEGF
PDCD1, VEGFAPhase 1Advanced Solid TumorJun 2027
RocheRO7247669
Anti-PD-1 and anti-LAG-3 bispecific antibody
PDCD1, LAG3Phase 1Solid TumorsJun 2027
West China HospitalPD-1/PD-L1 Inhibitor-Based Therapy
PD-1/PD-L1 inhibitor monotherapy or combination therapy
PDCD1, CD274Phase 1Solid TumorsJul 2027
Shanghai Henlius BiotechHLX18
PD-1 inhibitor
PDCD1Phase 1Esophageal and/or Cardia CancerAug 2027
Seqker Biosciencesanti-PD-1 immune checkpoint inhibitor
PD-1 checkpoint inhibitor
PDCD1Phase 1Solid TumorsAug 2027
Biocon Biologics UKBmab1700
PD-1 inhibitor (nivolumab biosimilar)
PDCD1Phase 1MelanomaAug 2027
Memorial Sloan Kettering Cancer CenterM28z1XXPD1DNR CAR T cells
Mesothelin-targeted CAR T cells with anti-PD1 component
MSLN, PDCD1Phase 1Malignant Pleural Mesothelioma (MPM); Mesothelin PositiveSep 2027
Shenyang Sunshine PharmaceuticalSSGJ-709
Bispecific antibody targeting PD-1 and LAG-3
PDCD1, LAG3Phase 1Advanced Malignant TumorsSep 2027
Alvotech SwissAVT32-DRL_PB
PD-1 inhibitor (pembrolizumab biosimilar)
PDCD1Phase 1MelanomaOct 2027
Tianjin Medical University Cancer Institute and HospitalGK01 cell injection
PD-1 inhibitor
PDCD1Phase 1Solid Tumors; Advanced Solid TumorsDec 2027
Biocon Biologics UKBmab1800
PD-1 inhibitor
PDCD1Phase 1Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)Dec 2027
M.D. Anderson Cancer CenterAnti-PD-1/PD-L1
PD-1/PD-L1 checkpoint inhibitor monoclonal antibodies
PDCD1, CD274Phase 1Advanced Malignant Solid NeoplasmFeb 2028
Ono PharmaceuticalONO-4538HSC
PD-1 inhibitor
PDCD1Phase 1Advanced or Metastatic Solid Tumors; Pediatric Malignant Solid Tumor and Epithelioid SarcomaFeb 2028
Immorna BiotherapeuticsJCXH-211
PD-1 checkpoint inhibitor
PDCD1Phase 1Malignant Solid TumorsMar 2028
MabQuestMAQ-001
Anti-PD-1 monoclonal antibody with alternative mechanism independent of PD-1/PD-L1 blockad
PDCD1Phase 1Advanced Solid TumorJun 2028
ImmVirxSintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 1Colorectal CancerJun 2028
Centre hospitalier de l'Université de Montréal (CHUM)Pulse radiotherapy combined with PD(L)-1 inhibitors
Pulsed radiotherapy combined with PD(L)-1 immune checkpoint inhibition
PDCD1, CD274Phase 1Non Small Cell Lung CancerJul 2028
Fundacio Clinic BarcelonaPD1+ TILs (NUMARZU-001)
PD1-positive tumor-infiltrating lymphocytes (TILs) adoptive cell therapy
PDCD1Phase 1Metastatic Triple-Negative Breast CarcinomaSep 2028
AkesoAK131
anti-PD-1 and CD73 bispecific antibody
PDCD1, NT5EPhase 1Solid TumorDec 2028
Ottimo PharmaOTP-01
Dual paratopic PD-1/VEGFR2 antibody
PDCD1, KDRPhase 1Advanced Solid TumorsDec 2028
Jiangsu Simcere PharmaceuticalSIM0689 for Injection
PD-1/VEGF bispecific antibody
PDCD1, VEGFAPhase 1Neoplasms, MalignantDec 2028
OSE ImmunotherapeuticsOSE-279
PD-1 blocking monoclonal antibody
PDCD1Phase 1Solid Advanced TumorDec 2029
Vanderbilt-Ingram Cancer Centernivolumab-IRDye800CW
PD-1 inhibitor conjugated to near-infrared fluorescent dye for molecular imaging
PDCD1Phase 1HnsccApr 2030
Australian & New Zealand Children's Haematology/Oncology GroupOpdualag
PD-1 and LAG-3 inhibitor combination
PDCD1, LAG3Phase 1Childhood CancerDec 2030
Han weidongAnti-PD-1 antibody
PD-1 inhibitor
PDCD1Phase 1Malignancies Multiple–
Amal TherapeuticsBI 754091
PD-1 inhibitor
PDCD1Phase 1Colorectal Cancer–
FormyconFYB206
PD-1 inhibitor (anti-PD-1 antibody)
PDCD1Phase 1Melanoma, Stage II–
invoX PharmaPembrolizumab (FS120)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Advanced Cancer–
Chen XiaozhongPenplimab Injection
PD-1 inhibitor
PDCD1Phase 1Metastatic Nasopharyngeal Carcinoma–
Binhui BiopharmaceuticalPucotenlimab (HX008)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Solid Tumor; Melanoma–
Fujian Haixi PharmaceuticalsSintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 1Solid Tumor–

Conditions

Melanoma (51) Breast Cancer (45) Gastric Cancer (44) Head and Neck Squamous Cell Carcinoma (43) Hepatocellular Carcinoma (41) Colorectal Cancer (41) Nasopharyngeal Carcinoma (41) Non Small Cell Lung Cancer (35) Non-small Cell Lung Cancer (35) Esophageal Squamous Cell Carcinoma (35) Non-Small Cell Lung Cancer (29) Cervical Cancer (26)

Modalities

mixed (70), antibody (58), small molecule (58), protein or peptide (10), other (8)

Companies

Tianjin Medical University Cancer Institute and Hospital (8) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) Sun Yat-sen University (8) Fudan University (6) Ruijin Hospital (6) Akeso (5) Second Affiliated Hospital, Zhejiang University, School of Medicine (5) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) Sichuan Baili Pharmaceutical (3) Innovent Biologics (Suzhou) (3) Shanghai Henlius Biotech (3) Peking University Cancer Hospital & Institute (3) Sixth Affiliated Hospital, Sun Yat-sen University (3) AstraZeneca (3) Shanghai Zhongshan Hospital (3) Shenyang Sunshine Pharmaceutical (3) Tongji Hospital (3) Regeneron Pharmaceuticals (2) West China Hospital (2) Ono Pharmaceutical (2)

Related targets

CTLA4 (30) CD274 (26) VEGFA (6) LAG3 (5) KDR (3) HAVCR2 (2) IL2 (2) TIGIT (2) ERBB2 (2) OPRM1 (2) IL2RA (2) GLP1R (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.